Your session is about to expire
← Back to Search
BNT141 for Esophageal Cancer
Study Summary
This trial is designed to find the best dose of BNT141 for treating patients with CLDN18.2-positive tumors who have no other treatment options. The trial will first test BNT141 alone and then in combination with nab-paclitaxel and gemcitabine. The trial will be conducted in three parts, with the third part to be added at a later stage.
- Esophageal Cancer
- Pancreatic Cancer
- Gastroesophageal Junction Adenocarcinoma
- Stomach Cancer
- Cancer
- Solid Tumors
- Biliary Tract Cancer
- Bile Duct Cancer
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a type of cancer that has spread to other parts of the body and cannot be completely removed by surgery.You have received treatment with a certain type of medication that targets CLDN18.2, except for a specific one called BNT141.
- Group 1: Part 1A - BNT141 monotherapy escalation
- Group 2: Part 1B - BNT141 in combination with nab-paclitaxel and gemcitabine
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many facilities are currently administering this trial?
"There are 7 distinct medical centres participating in this clinical trial, including MD Anderson Cancer Center of Houston, START in Duarte and City of Hope in Montréal."
Is it feasible to enroll new participants in this experiment?
"The findings on clinicaltrials.gov suggest that as of 11/29/2022, this experiment is still recruiting participants. It was initially posted to the database on 1/18/2022."
What is the total sample size of this clinical research?
"Affirmative. Clinicaltrials.gov have the latest information, which shows that this trial began recruitment on January 18th 2022 and is still searching for participants today. 96 patients need to be enrolled from 7 different locations."
Share this study with friends
Copy Link
Messenger